China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent
We listed the key points about healthcare industry in 2022Â government work report. Companies should notice the skyrocketed experimental monkey...
333 Views
Pre-IPO Shanghai NewMed Medical - Concerns on Fierce Competition and Future Commercialization
We analyzed the industry characteristics of heart valve device market. Concerns of NewMed are mainly the slow product development progress, fierce...
447 Views
Peijia Medical (9996.HK) Vs Venus MedTech (2500.HK) Vs CardioFlow (2160.HK)-Pain Points and Solution
We analyzed the TAVR business of Venus, MicroPort CardioFlow and Peijia. We also analyzed the competition pattern, concerns, pain points of TAVR...
401 Views
China Healthcare Weekly (Jan.7)-China's Drug Spending,Logic Behind China/US Biotech, Anesthetics VBP
The insight mainly analyzed the relationship of drug spending with GDP growth, different logic behind China/US biotech companies and related risks...
425 Views
MicroPort MedBot IPO Trading - Decent Demand But Upside Is Limited from the Top-End
Shanghai MicroPort MedBot Group (MM), a surgical robot company, raised around US$200m in its Hong Kong IPO. In this note we will talk about the...
358 Views